TOKYO, Japan – Japanese pharmaceutical firm Takeda stated the European Union had given the inexperienced mild to its dengue fever vaccine, making it the second jab stopping the illness to be authorised by the bloc.
Mosquito-borne dengue may cause hemorrhagic fever and infects an estimated 100 to 400 million folks yearly, though over 80 % of instances are gentle or asymptomatic, the WHO says.
Takeda Pharmaceutical stated its vaccine, marketed as Qdenga, was given regulatory approval by the European Commission on Thursday for folks aged 4 and above, no matter their virus publicity historical past.
Another dengue vaccine, Dengvaxia — the world’s first towards the illness — is already out there within the European Union, however solely for many who have had a beforehand confirmed an infection.
Dengvaxia turned the topic of controversy in 2019 when the Philippines banned it over security considerations, claims which its maker, French pharmaceutical large Sanofi, denies.
Qdenga was authorised in Indonesia earlier this 12 months for these aged six and up.
The variety of reported dengue instances has elevated greater than eightfold within the final twenty years, in accordance with the World Health Organization, which says “about half of the world’s population (is) now at risk”. — Agence France-Presse
